05 July 2018
U.S. drug contract manufacturer Catalent said it will buy Juniper Pharmaceuticals for $11.50 per share in cash. The offer price represents a premium of about 32 per cent to Juniper Pharmaceuticals’ closing price of $8.70 and values the company at about $127.7 million.
Catalent has a market value of about $5.58 billion.
Juniper Pharmaceuticals shares are up more than 22 per cent since January, when the company said it was exploring strategic alternatives. The deal includes Juniper Pharmaceuticals’ U.K. business, Juniper Pharma Services, and is expected to close in the first quarter of 2019, Catalent said in a statement.
Catalent said it would continue to support Juniper’s Crinone franchise, a progesterone gel which is its single largest revenue source and marketed by Merck outside of the United States. Juniper Pharmaceuticals separately said its board had unanimously approved the deal which represents a total equity value of about $139.6 million on a fully-diluted basis.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.
21 June 2019
There is an increasing focus to identify diseases that currently do not have a vaccine.
20 June 2019
The market for ophthalmic drugs is a growing one.